Dyadic International, Inc. DYAI · Stock Open Dyadic International, Inc. in new tab
Dyadic International, Inc. Analysis (DYAI)
Is Dyadic International, Inc. a good investment? Dyadic International, Inc. (DYAI) is currently trading at 0.4010 USD. Market analysts have a consensus price target of 5.50 USD. This suggests a potential upside from current levels.
Earnings Schedule: Dyadic International, Inc. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -0.32.
Investor FAQ
Does Dyadic International, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Dyadic International, Inc.?
Dyadic International, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -0.20.
Company Profile
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Community Discussion